Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
By purchasing, you acknowledge this product is for research use only
Razlozi su razliiti: cena, nuspojave, oekivanja, zamor od terapije ili utisak da je cilj ve postignut
Open 6 , e2330885 (2023)
Dec 21: The FDA on Thursday signed off on the first and only self-administered treatment for polyneuropathy in hereditary transthyretin-mediated amyloidosis (hATTR-PN): AstraZeneca and Ionis eplontersen, now to be known as Wainua
Mass spectrometry-based microassay of 2H and 13C plasma glucose labeling to quantify liver metabolic fluxes in vivo
US$ 27.43
US$ 26.78
US$ 20.59
US$ 23.65
US$ 27.14
